IRIS UniCatt

Lorusso, Domenica
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.142
NA - Nord America 3.139
EU - Europa 2.103
SA - Sud America 619
AF - Africa 76
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 4
Totale 9.089
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.012
SG - Singapore 1.303
CN - Cina 855
IT - Italia 520
BR - Brasile 507
DE - Germania 458
SE - Svezia 282
VN - Vietnam 250
FR - Francia 178
IN - India 167
IE - Irlanda 133
GB - Regno Unito 112
ID - Indonesia 94
BD - Bangladesh 92
UA - Ucraina 92
JP - Giappone 84
HK - Hong Kong 79
FI - Finlandia 70
RU - Federazione Russa 69
CA - Canada 62
AR - Argentina 52
KR - Corea 37
MX - Messico 37
TR - Turchia 35
AT - Austria 30
ES - Italia 29
NL - Olanda 29
ZA - Sudafrica 27
IQ - Iraq 25
BE - Belgio 22
PL - Polonia 22
PK - Pakistan 19
VE - Venezuela 16
IR - Iran 15
EC - Ecuador 13
SA - Arabia Saudita 13
PH - Filippine 12
CH - Svizzera 10
CL - Cile 10
CO - Colombia 10
LT - Lituania 10
MA - Marocco 10
RO - Romania 10
JO - Giordania 9
CI - Costa d'Avorio 8
KE - Kenya 8
EG - Egitto 7
JM - Giamaica 7
KZ - Kazakistan 7
IL - Israele 6
PY - Paraguay 6
TN - Tunisia 6
AU - Australia 5
AZ - Azerbaigian 5
CZ - Repubblica Ceca 5
HN - Honduras 5
KG - Kirghizistan 5
MY - Malesia 5
UZ - Uzbekistan 5
AE - Emirati Arabi Uniti 4
CR - Costa Rica 4
DZ - Algeria 3
ET - Etiopia 3
GE - Georgia 3
HU - Ungheria 3
OM - Oman 3
AL - Albania 2
AW - Aruba 2
BG - Bulgaria 2
BY - Bielorussia 2
CW - ???statistics.table.value.countryCode.CW??? 2
GR - Grecia 2
GT - Guatemala 2
LK - Sri Lanka 2
NP - Nepal 2
PA - Panama 2
PE - Perù 2
QA - Qatar 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
DO - Repubblica Dominicana 1
EE - Estonia 1
EU - Europa 1
FK - Isole Falkland (Malvinas) 1
GD - Grenada 1
GY - Guiana 1
LB - Libano 1
LV - Lettonia 1
MT - Malta 1
NG - Nigeria 1
NO - Norvegia 1
PT - Portogallo 1
SI - Slovenia 1
Totale 9.085
Salva come PNG Salva come JPEG
Città #
Singapore 684
San Jose 406
Ashburn 370
Chandler 278
Hangzhou 188
Beijing 163
Dublin 129
Rome 114
Hyderabad 106
New York 104
Hefei 99
Ho Chi Minh City 90
Los Angeles 87
Jakarta 80
Hong Kong 74
Tokyo 74
Lauterbourg 68
Milan 68
Wilmington 63
San Mateo 60
The Dalles 55
Hanoi 53
Frankfurt am Main 51
Jacksonville 48
Boston 47
Nanjing 42
Munich 40
São Paulo 40
Santa Clara 38
Helsinki 37
Moscow 37
Buffalo 35
Dallas 32
Kent 32
Cattolica 31
Seoul 31
Princeton 29
Council Bluffs 25
Bar Harbor 24
Houston 24
Orem 23
Zhengzhou 22
Boardman 21
Redwood City 21
Dearborn 20
Seattle 20
Toronto 20
Washington 18
Atlanta 17
Brussels 17
Chicago 17
Da Nang 17
Lawrence 17
Fairfield 16
Nanchang 16
Phoenix 16
Ann Arbor 15
Brooklyn 15
Haiphong 15
Montreal 15
Nuremberg 15
St Louis 15
Vienna 15
Bremen 14
Marseille 14
Mexico City 14
Naples 14
Rio de Janeiro 14
Düsseldorf 13
Izmir 13
Johannesburg 13
Paris 13
Shanghai 13
Bari 12
London 12
Mountain View 12
Woodbridge 12
Denver 11
Palermo 11
Baghdad 10
Guangzhou 10
Porto Alegre 10
Portsmouth 10
Amman 9
Belo Horizonte 9
Brasília 9
Dhaka 9
Nürnberg 9
Poplar 9
Stockholm 9
Tukwila 9
Abidjan 8
Amsterdam 8
Andover 8
Bologna 8
Busto Arsizio 8
Lappeenranta 8
Manchester 8
Newark 8
Richardson 8
Totale 4.848
Salva come PNG Salva come JPEG
Nome #
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 525
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial 362
Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine 214
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. 199
Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol 186
Sonographic imaging of urinoma 175
Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia) 175
The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma 171
Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer 167
Prolonged chemoradiation in locally advanced carcinoma of the uterine cervix: final results of a phase ii study (ester-1). 164
Building a personalized medicine infrastructure for gynecological oncology patients in a high-volume hospital 148
Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification 143
Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer 143
Stereotactic radiotherapy in recurrent gynecological cancer: a case series 141
Impact of Comprehensive Genome Profiling on the Management of Advanced Non–Small Cell Lung Cancer: Preliminary Results From the Lung Cancer Cohort of the FPG500 Program 139
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma 127
Advanced and recurrent endometrial cancer: State of the art and future perspectives 125
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study 124
PARP Inhibitors Resistance: Mechanisms and Perspectives 119
The immunohistochemical molecular risk classification in endometrial cancer: A pragmatic and high-reproducibility method 119
Recent progress in the use of pharmacotherapy for endometrial cancer 118
Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery 117
ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease 117
Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer 117
1st Evidence-based Italian consensus conference on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis from ovarian cancer 116
A clinical ultrasound algorithm to identify uterine sarcoma and smooth muscle tumors of uncertain malignant potential in patients with myometrial lesions: the MYometrial Lesion UltrasouNd And mRi study 114
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial 113
Endometrial carcinosarcoma 113
Role of Homologous Recombination Repair (HRR) Genes in Uterine Leiomyosarcomas: A Retrospective Analysis 113
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial 111
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis 110
Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO 109
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials 109
Lynch Syndrome and Gynecologic Tumors: Incidence, Prophylaxis, and Management of Patients with Cancer 109
Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study 108
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? 107
A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms 106
Oregovomab: an investigational agent for the treatment of advanced ovarian cancer 104
Is the endometrial evaluation routinely required in patients with adult granulosa cell tumors of the ovary? 102
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 101
Sonographic imaging of urinoma. 101
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial 101
The role of artificial intelligence in managing multimorbidity and cancer 100
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial 99
Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study 99
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial 99
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 98
Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score–matched analysis 97
Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: The MITO-8,MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study 97
Newly diagnosed ovarian cancer: Which first-line treatment? 96
Past, present and future of adjuvant HIPEC in patients at high risk for colorectal peritoneal metastases 95
Knowledge and attitudes towards clinical trials among women with ovarian cancer: results of the ACTO study 94
Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives 92
Clear cell carcinoma of the endometrium 91
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: A retrospective MITO group study 91
Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: Predictive value of DNA-PK and phosphorylated ACC 90
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy 87
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients with Recurrent Ovarian Carcinoma 87
Successful pregnancy in stage IE primary non-Hodgkin's lymphoma of uterine cervix treated with neoadjuvant chemotherapy and conservative surgery 86
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome 85
Diagnosis of uterine leiomyosarcoma 5 years after magnetic-resonance-guided high-intensity focused ultrasound treatment of fibroid 84
Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19) 83
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial 81
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 81
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 79
New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere 79
Effects of niraparib dose reduction on short-term outcomes in ovarian cancer patients 77
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial 76
Management of stage III and IVa uterine cancer 74
Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26) 73
Dostarlimab: From preclinical investigation to drug approval and future directions 72
Successful pregnancy in stage IE primary non-Hodgkin's lymphoma of uterine cervix treated with neoadjuvant chemotherapy and conservative surgery 72
Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer 72
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel 72
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer 70
Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: A retrospective MITO group study 70
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer 70
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup 67
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma 67
Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial 67
Late isolated subcutaneous recurrence in an endometrial cancer patient submitted to panniculectomy 66
Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification 65
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial 56
Use of adjuvant therapy in patients with FIGO stage III endometrial carcinoma: A multicenter retrospective study 54
Chemotherapy-free treatments: Are we ready for prime time? 50
Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome) 48
Integration of PARP-inhibitors in ovarian cancer therapy 6
Homologous recombination deficiency in Ovarian cancer: The game-changer for first-line maintenance therapy 6
Ovarian cancer treatments strategy: Focus on parp inhibitors and immune check point inhibitors 5
Immunotherapy in gynecological cancers 4
Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study 3
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study 3
ENDOESTRO score: Where is the dark side? Evaluation of estrogen receptor expression cutoff in endometrial cancer molecular classification, an ambispective study 3
Tisotumab Vedotin in Cervical Cancer: Current Status and Future Perspectives 3
Antibody drug conjugates in recurrent or metastatic cervical cancer: a focus on tisotumab vedotin state of art 1
Totale 9.624
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.644
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.644
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022392 32 21 10 23 24 5 11 60 15 24 61 106
2022/2023896 89 104 60 91 70 114 34 70 136 32 54 42
2023/2024762 19 197 51 48 32 108 71 13 23 35 79 86
2024/20251.700 35 40 121 61 97 59 86 74 206 229 378 314
2025/20264.142 548 133 306 502 609 226 595 198 322 291 205 207
2026/2027155 155 0 0 0 0 0 0 0 0 0 0 0
Totale 9.624